Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $14.50.

A number of research firms have recently issued reports on TBPH. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price on the stock in a report on Tuesday. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th.

Theravance Biopharma Stock Up 0.1%

Shares of NASDAQ:TBPH traded up $0.01 during midday trading on Tuesday, reaching $10.63. The company's stock had a trading volume of 193,858 shares, compared to its average volume of 274,417. The firm has a 50 day moving average of $9.74 and a 200-day moving average of $9.47. The firm has a market capitalization of $531.50 million, a P/E ratio of -9.01 and a beta of -0.09. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. The company had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. On average, research analysts predict that Theravance Biopharma will post -1.09 EPS for the current year.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 370,038 shares of the company's stock, valued at approximately $3,330,342. This trade represents a 1.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nuveen LLC purchased a new position in shares of Theravance Biopharma in the 1st quarter worth approximately $3,348,000. Newtyn Management LLC boosted its stake in Theravance Biopharma by 5.7% in the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock valued at $44,767,000 after acquiring an additional 258,337 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Theravance Biopharma by 121,993.7% in the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after purchasing an additional 174,451 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Theravance Biopharma by 20.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock worth $5,211,000 after purchasing an additional 95,304 shares in the last quarter. Finally, Jane Street Group LLC increased its position in shares of Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock worth $1,258,000 after purchasing an additional 88,540 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.